{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/de-risking-patient-journey-cell-therapies#webpage",
"url": "https://www.fortrea.com/insights/de-risking-patient-journey-cell-therapies",
"name": "De-risking the patient journey in cell therapies",
"description": "This Fortrea white paper explores the cell and gene therapy patient journey and the considerations affecting patient-centered planning across advanced therapy clinical development environments. The content focuses on cell and gene therapy patient journey planning, patient access considerations, treatment coordination, long-term follow-up requirements, and operational considerations associated with advanced therapy programs. The white paper highlights challenges related to care pathway coordination, patient engagement, treatment site planning, long-term monitoring, and operational readiness affecting cell and gene therapy clinical development. Fortrea discusses approaches designed to support patient-centered planning, strengthen coordination across treatment pathways, and address considerations associated with evolving advanced therapy environments. By integrating patient journey planning with operational coordination and long-term follow-up considerations, the white paper provides insights into de-risking the patient journey in cell and gene therapy clinical development and broader advanced therapy programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "De-risking the patient journey in cell therapies",
"item": "https://www.fortrea.com/insights/de-risking-patient-journey-cell-therapies"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/de-risking-patient-journey-cell-therapies#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/de-risking-patient-journey-cell-therapies#webpage"
},
"headline": "De-Risking the Patient Journey in Cell and Gene Therapy Clinical Development | Fortrea White Paper",
"description": "This Fortrea white paper explores the cell and gene therapy patient journey and the considerations affecting patient-centered planning across advanced therapy clinical development environments. The content focuses on cell and gene therapy patient journey planning, patient access considerations, treatment coordination, long-term follow-up requirements, and operational considerations associated with advanced therapy programs. The white paper highlights challenges related to care pathway coordination, patient engagement, treatment site planning, long-term monitoring, and operational readiness affecting cell and gene therapy clinical development. Fortrea discusses approaches designed to support patient-centered planning, strengthen coordination across treatment pathways, and address considerations associated with evolving advanced therapy environments. By integrating patient journey planning with operational coordination and long-term follow-up considerations, the white paper provides insights into de-risking the patient journey in cell and gene therapy clinical development and broader advanced therapy programs.",
"genre": "White Paper",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-21",
"dateModified": "2024-10-21",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0007_CGT_De-risking%20the%20Patient%20Journey_0823_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}